65-- XIENCE V (Trademark), Everolimus Drug Eluting Stents

Replacement of FBO notice VA-244-10-RP-0414 The VA Pittsburgh Healthcare System (VAPHS) intends to negotiate on a sole source basis, pursuant to the authority at FAR 6.302-2, for XIENCEâ„¢ V, Everolimus drug eluting stents, available only from Abbott Laboratories Inc., 100 Abbott Park Road, Abbott Park, IL 60064-3500. The XIENCEâ„¢ V is one of two available brand name products for the Everolimus medicated drug eluting stents which VAPHS cardiac surgeons have determined to be the most medically effective. The VAPHS will separately publicize its intent to negotiate for the other brand name Everolimus drug eluting stent. This notice of Intent is NOT a request for competitive proposals. Interested parties may identify their interest and capability to meet this requirement by contacting the Contracting Office no later than Friday, September 10, 2010, 4:30 p.m. Interest/capability statements may be sent to Paula Stankovic at [email protected]. No telephone responses will be accepted. It is the Government's belief that at this time, only one source is capable of providing the XIENCEâ„¢ V, in order to satisfy VAPHS' requirement for use of Everolimus drug eluting stents only. VAPHS will consider any and all interest & capability statements received; however, the final determination by the Government not to compete this proposed procurement is solely within its discretion.